{"id":1913,"date":"2024-12-21T16:57:10","date_gmt":"2024-12-21T13:57:10","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=1913"},"modified":"2025-06-21T13:49:54","modified_gmt":"2025-06-21T10:49:54","slug":"uk-approves-givinostat-duvyzat-for-duchenne-muscular-dystrophy-treatment","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/ru\/uk-approves-givinostat-duvyzat-for-duchenne-muscular-dystrophy-treatment\/","title":{"rendered":"\u0412\u0435\u043b\u0438\u043a\u043e\u0431\u0440\u0438\u0442\u0430\u043d\u0438\u044f \u043e\u0434\u043e\u0431\u0440\u0438\u043b\u0430 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442 \u0413\u0438\u0432\u0438\u043d\u043e\u0441\u0442\u0430\u0442 (Duvyzat) \u0434\u043b\u044f \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u043c\u044b\u0448\u0435\u0447\u043d\u043e\u0439 \u0434\u0438\u0441\u0442\u0440\u043e\u0444\u0438\u0438 \u0414\u044e\u0448\u0435\u043d\u043d\u0430"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In a significant development for patients with Duchenne muscular dystrophy (DMD), the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for the medicine givinostat, also known as Duvyzat.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This approval, announced on 20 December 2024, marks a crucial step forward in the treatment of this debilitating genetic disorder.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Givinostat is a nonsteroidal drug indicated for the treatment of patients aged 6 years of age and older with all genetic variants of DMD. [Read more: <a href=\"https:\/\/dmdwarrior.com\/duvyzat-givinostat-nonsteroidal-drug\/\" target=\"_blank\" data-type=\"post\" data-id=\"1462\" rel=\"noreferrer noopener\">What is Duvyzat (Givinostat)?<\/a>]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD). In a significant development for patients with Duchenne muscular dystrophy (DMD), the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for the medicine givinostat, also known as Duvyzat. This approval, announced on 20 December 2024, marks a crucial step [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1916,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45],"tags":[46,49,47,50,48],"class_list":["post-1913","post","type-post","status-publish","format-standard","has-post-thumbnail","category-approved-therapies-for-duchenne-muscular-dystrophy","tag-duvyzat","tag-england","tag-givinostat","tag-mhra","tag-uk"],"subtitle":"\u0423\u0441\u043b\u043e\u0432\u043d\u043e\u0435 \u043e\u0434\u043e\u0431\u0440\u0435\u043d\u0438\u0435 MHRA \u043f\u043e\u0437\u0432\u043e\u043b\u044f\u0435\u0442 \u0438\u0441\u043f\u043e\u043b\u044c\u0437\u043e\u0432\u0430\u0442\u044c \u0433\u0438\u0432\u0438\u043d\u043e\u0441\u0442\u0430\u0442 \u0443 \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u043e\u0432 \u0441 \u041c\u0414\u0414 \u0432 \u0432\u043e\u0437\u0440\u0430\u0441\u0442\u0435 \u043e\u0442 \u0448\u0435\u0441\u0442\u0438 \u043b\u0435\u0442 \u0438 \u0441\u0442\u0430\u0440\u0448\u0435, \u0438 \u043e\u043d\u043e \u043f\u0440\u0438\u043c\u0435\u043d\u0438\u043c\u043e \u043a\u043e \u0432\u0441\u0435\u043c \u0433\u0435\u043d\u0435\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u043c \u0432\u0430\u0440\u0438\u0430\u043d\u0442\u0430\u043c \u044d\u0442\u043e\u0433\u043e \u0441\u043e\u0441\u0442\u043e\u044f\u043d\u0438\u044f. \u042d\u0442\u043e \u0440\u0435\u0448\u0435\u043d\u0438\u0435 \u043f\u043e\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043b\u043e \u0437\u0430 \u043e\u0434\u043e\u0431\u0440\u0435\u043d\u0438\u0435\u043c \u0433\u0438\u0432\u0438\u043d\u043e\u0441\u0442\u0430\u0442\u0430 \u0423\u043f\u0440\u0430\u0432\u043b\u0435\u043d\u0438\u0435\u043c \u043f\u043e \u043a\u043e\u043d\u0442\u0440\u043e\u043b\u044e \u0437\u0430 \u043f\u0440\u043e\u0434\u0443\u043a\u0442\u0430\u043c\u0438 \u0438 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0430\u043c\u0438 \u0421\u0428\u0410 (FDA) \u0432 \u043d\u0430\u0447\u0430\u043b\u0435 \u044d\u0442\u043e\u0433\u043e \u0433\u043e\u0434\u0430.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/posts\/1913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/comments?post=1913"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/posts\/1913\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/media\/1916"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/media?parent=1913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/categories?post=1913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/ru\/wp-json\/wp\/v2\/tags?post=1913"}],"curies":[{"name":"WP","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}